The Prescribing Patterns of Antipsychotic Drugs and Antiparkinsonian Drugs in Elderly Patients with Dementia |
Yoon, Soo Mi
(College of Pharmacy, Dongduk Women's University)
Lee, Sungwon (Department of Psychiatry, Yonsei University College of Medicine) Chang, Ji-Eun (College of Pharmacy, Dongduk Women's University) Lee, Young Sook (Department of Pharmacy, Keimyung University) Rhew, Kiyon (College of Pharmacy, Dongduk Women's University) |
1 | Demographics by age; Ministry of Health and Welfare. Available from http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=343379&page=1. Accessed June 20, 2018. |
2 | Prevalence of dementia in Korea; Ministry of Health and Welfare. Available from http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&BOARD_ID=140&BOARD_FLAG=00&CONT_SEQ=286138&page=1. Accessed June 20, 2018. |
3 | Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608. DOI |
4 | Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-9. DOI |
5 | Koponen M, Taipale H, Lavikainen P. et al. Risk of mortality associated with antipsychotic monotherapy and polypharmacy among community-dwelling persons with alzheimer’s disease. J Alzheimers Dis 2017;56:107-18. |
6 | Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000;22:195-214. DOI |
7 | Corbett A, Burns A, Ballard C. Don’t use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ 2014;349:g6420. DOI |
8 | Reus VI, Fochtmann LJ, Eyler AE, et al. The American psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 2016;173:543-6. |
9 | Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005; ;293(20):2462. DOI |
10 | Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210. DOI |
11 | Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000;61:16-21. DOI |
12 | Lucca JM, Ramesh M, Parthasarathi G, Raman R. An adverse drug interaction of haloperidol with levodopa. Indian J Psychol Med. 2015;37:220-2. DOI |
13 | Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’experience in a regional pharmacovigilance center in France. Mov Disord 2011;26:2226-31. DOI |
14 | Klaus T. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003;38:843-53. DOI |
15 | Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008. |
16 | NICE Guideline. Antipsychotics in people living with dementia. Available from https://www.nice.org.uk/advice/ktt7/. Accessed June 20, 2018. |
17 | Kochi K, Sato I, Nishiyama C, et al. Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study. Pharmacoepidemiol Drug Saf 2017;26:642-56 DOI |
18 | Schulze J, Glaeske G, van den Bussche H, et al. Prescribing of antipsychotic drugs in patients with dementia: a comparison with age-matched and sex-matched non-demented controls. Pharmacoepidemiol Drug Saf. 2013;22:1308-16. DOI |
19 | Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S. Antipsychotic polypharmacy among a nationwide sample of community-dwelling persons with Alzheimer’s disease. J Alzheimers Dis 2014;41: 1223-8. |
20 | Stephens P, Chikh K, Leufkens H. Prescribing of antipsychotics in people with dementia in acute general hospitals in England: 2010-2012. Eur Geriatr Med 2014;5:394-8. DOI |
21 | Youn KI. Comparisons of health care utilization patterns and outcome for national health insurance and medical aid program cancer patients. J Health Info Stat. 2014;39:42-59. |
22 | Park YH, Lee YJ. Qualitative analysis of medical usage patterns of medical aid patients. The Journal of the Korea Contents Association. 2017;17:39-49. |
23 | Lee YJ. Differences of cancer patient's health care utilizations between medical aid program and National Health Insurance in the elderly. The Journal of the Korea Contents Association. 2011;11:270-9. |
24 | Hawkins T, Berman BD. Pimavanserin: A novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract. 2017;7:157-162. |
25 | Fox SH. Pimavanserin as treatment for Parkinson’s disease psychosis. Lancet 2014;383:494-6. DOI |